Amgen will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology Annual Meeting from May 31 to June 4 in Chicago. Abstracts will include study results on talimogene laherparepvec, an investigational oncolytic immunotherapy for the treatment of melanoma; blinatumomab in pediatric patients with acute lymphoblastic leukemia; and Vectibix (panitumumab) in metastatic colorectal cancer.